Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Global Response To Swine Flu Unprecedented; Vaccine Makers Ready To Switch

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - For the first time in history, the emergence and spread of a pandemic is being tracked globally and in real time. The result has been a coordinated global response from countries both affected and unaffected as well as participation from the private sector

You may also be interested in...



Korea Expands National Medical Insurance Coverage Of Tamiflu, Relenza To Fight Swine Flu

SEOUL - With global health authorities warning of the possibility of the swine flu blooming into a pandemic, Korea's Ministry for Health, Welfare and Family Affairs has begun to cover Roche's Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir) under the National Medical Insurance System for those likely exposed to the swine flu

As Swine Flu Transcends Boundaries, Cipla Steps In To Supply Oseltamivir

MUMBAI - Known for supplies of cheap anti-retroviral drugs to major African nations, Indian drug maker Cipla has offered to make available 1.5 million dosage of Tamiflu generic oseltamivir within the next 4 to 6 weeks to control the further spread of the dreaded swine flu

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel